StockData
Kiniksa Pharmaceuticals International, plc logo

Kiniksa Pharmaceuticals International, plc (KNSA) stock

KNSANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 27, 2026Score 14/30469% above fair value
$95.05−0.06 (-0.06%)

Close on Nov 18, 2026Market cap $14.94BP/E 73.1Yield –

Kiniksa Pharmaceuticals International revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Kiniksa Pharmaceuticals International's revenue for the twelve months ending Sep 30, 2026 was $945.96M, up 58.2% year over year. For fiscal 2025 it was $677.56M, up 60.1% from the year before. The highest annual figure on record is $677.56M in fiscal 2025.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$677.56M+60.1%
FY2024Dec 31, 2024$423.24M+56.6%
FY2023Dec 31, 2023$270.26M+22.7%
FY2022Dec 31, 2022$220.18M+471.2%
FY2021Dec 31, 2021$38.54M–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$285.97M+58.1%
Q2 FY2026Jun 30, 2026$243.60M+55.4%
Q1 FY2026Mar 31, 2026$214.27M+55.5%
Q4 FY2025Dec 31, 2025$202.13M+65.0%
Q3 FY2025Sep 30, 2025$180.86M+61.2%
Q2 FY2025Jun 30, 2025$156.80M+44.3%
Q1 FY2025Mar 31, 2025$137.79M+72.5%
Q4 FY2024Dec 31, 2024$122.54M+46.9%
Q3 FY2024Sep 30, 2024$112.21M+67.4%
Q2 FY2024Jun 30, 2024$108.63M+52.0%
Q1 FY2024Mar 31, 2024$79.86M+65.2%
Q4 FY2023Dec 31, 2023$83.40M+34.8%
Q3 FY2023Sep 30, 2023$67.05M-32.4%
Q2 FY2023Jun 30, 2023$71.47M+165.0%
Q1 FY2023Mar 31, 2023$48.35M+50.2%
Q4 FY2022Dec 31, 2022$61.88M+230.1%
Q3 FY2022Sep 30, 2022$99.14M+719.6%
Q2 FY2022Jun 30, 2022$26.97M+250.1%
Q1 FY2022Mar 31, 2022$32.19M–
Q4 FY2021Dec 31, 2021$18.75M–
Q3 FY2021Sep 30, 2021$12.10M–
Q2 FY2021Jun 30, 2021$7.70M–

More Kiniksa Pharmaceuticals International figures

See a number that looks wrong?